Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

V. Polivkova, P. Rohon, H. Klamova, O. Cerna, M. Divoka, N. Curik, J. Zach, M. Novak, I. Marinov, S. Soverini, E. Faber, K. Machova Polakova,

. 2016 ; 11 (5) : e0155959. [pub] 20160523

Language English Country United States

Document type Case Reports, Journal Article

Persistent link   https://www.medvik.cz/link/bmc17031715

Grant support
NT13899 MZ0 CEP Register

Bone marrow transplantation or ponatinib treatment are currently recommended strategies for management of patients with chronic myeloid leukemia (CML) harboring the T315I mutation and compound or polyclonal mutations. However, in some individual cases, these treatment scenarios cannot be applied. We used an alternative treatment strategy with interferon-α (IFN-α) given solo, sequentially or together with TKI in a group of 6 cases of high risk CML patients, assuming that the TKI-independent mechanism of action may lead to mutant clone repression. IFN-α based individualized therapy decreases of T315I or compound mutations to undetectable levels as assessed by next-generation deep sequencing, which was associated with a molecular response in 4/6 patients. Based on the observed results from immune profiling, we assumed that the principal mechanism leading to the success of the treatment was the immune activation induced with dasatinib pre-treatment followed by restoration of immunological surveillance after application of IFN-α therapy. Moreover, we showed that sensitive measurement of mutated BCR-ABL1 transcript levels augments the safety of this individualized treatment strategy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031715
003      
CZ-PrNML
005      
20191025091359.0
007      
ta
008      
171025s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0155959 $2 doi
035    __
$a (PubMed)27214026
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Polívková, Václava $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Faculty of Science, Charles University, Prague, Czech Republic. $7 xx0106968
245    10
$a Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients / $c V. Polivkova, P. Rohon, H. Klamova, O. Cerna, M. Divoka, N. Curik, J. Zach, M. Novak, I. Marinov, S. Soverini, E. Faber, K. Machova Polakova,
520    9_
$a Bone marrow transplantation or ponatinib treatment are currently recommended strategies for management of patients with chronic myeloid leukemia (CML) harboring the T315I mutation and compound or polyclonal mutations. However, in some individual cases, these treatment scenarios cannot be applied. We used an alternative treatment strategy with interferon-α (IFN-α) given solo, sequentially or together with TKI in a group of 6 cases of high risk CML patients, assuming that the TKI-independent mechanism of action may lead to mutant clone repression. IFN-α based individualized therapy decreases of T315I or compound mutations to undetectable levels as assessed by next-generation deep sequencing, which was associated with a molecular response in 4/6 patients. Based on the observed results from immune profiling, we assumed that the principal mechanism leading to the success of the treatment was the immune activation induced with dasatinib pre-treatment followed by restoration of immunological surveillance after application of IFN-α therapy. Moreover, we showed that sensitive measurement of mutated BCR-ABL1 transcript levels augments the safety of this individualized treatment strategy.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x farmakologie $7 D000971
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a bcr-abl fúzní proteiny $x účinky léků $x genetika $7 D016044
650    _2
$a vysoce účinné nukleotidové sekvenování $x metody $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a interferon alfa $x aplikace a dávkování $x farmakologie $7 D016898
650    _2
$a chronická myeloidní leukemie $x farmakoterapie $x genetika $7 D015464
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a individualizovaná medicína $7 D057285
650    _2
$a inhibitory proteinkinas $x aplikace a dávkování $x farmakologie $7 D047428
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rohoň, Peter $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and Faculty Hospital, Olomouc, Czech Republic. $7 ola2009507853
700    1_
$a Klamová, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Institute of Clinical and Experimental Hematology of the 1st Medicine Faculty, Charles University, Prague, Czech Republic. $7 xx0081721
700    1_
$a Černá, Olga $u Department of Internal Medicine and Hematology, 3rd Faculty of Medicine and Faculty Hospital Kralovske Vinohrady, Charles University, Prague, Czech Republic. $7 xx0111452
700    1_
$a Divoká, Martina $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and Faculty Hospital, Olomouc, Czech Republic. $7 xx0066076
700    1_
$a Čuřík, Nikola $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0230099
700    1_
$a Zach, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 _AN088059
700    1_
$a Novák, Martin $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and Faculty Hospital, Olomouc, Czech Republic. $7 xx0173369
700    1_
$a Marinov, Iuri $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0018261
700    1_
$a Soverini, Simona $u Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.
700    1_
$a Faber, Edgar, $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and Faculty Hospital, Olomouc, Czech Republic. $d 1956- $7 xx0062699
700    1_
$a Machová, Kateřina $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Institute of Clinical and Experimental Hematology of the 1st Medicine Faculty, Charles University, Prague, Czech Republic. $7 xx0139783
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 11, č. 5 (2016), s. e0155959
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27214026 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20191025091835 $b ABA008
999    __
$a ok $b bmc $g 1255308 $s 992742
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 11 $c 5 $d e0155959 $e 20160523 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a NT13899 $p MZ0
LZP    __
$a Pubmed-20171025

Find record

Citation metrics

Archiving options